Diseases, The Gut Microbiome
Promising Therapy in Parkinson’s Disease
Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, emerge as promising therapeutic agents in Parkinson’s disease (PD).
They target the gut-brain axis, mitigating alpha-synuclein (α-syn) pathology, reducing neuroinflammation, and enhancing dopaminergic function.
PD patients exhibit gut dysbiosis with reduced SCFA-producing bacteria (e.g., Faecalibacterium prausnitzii, Roseburia spp.) and lower fecal/plasma SCFA levels, correlating with motor severity, progression, and non-motor symptoms like constipation and depression.
SCFAs counteract these via HDAC inhibition, GPCR activation (e.g., FFAR2/3, GPR109A), and barrier restoration, with preclinical models showing neuroprotection and symptom alleviation.
Recent advances in 2024–2025, including prodrug conjugates and microbiome modulation, position SCFAs as adjuncts to levodopa, addressing dysbiosis-driven treatment resistance.
Key Mechanisms
SCFAs influence PD through interconnected pathways, primarily via microbial metabolite signaling:
They target the gut-brain axis, mitigating alpha-synuclein (α-syn) pathology, reducing neuroinflammation, and enhancing dopaminergic function.
PD patients exhibit gut dysbiosis with reduced SCFA-producing bacteria (e.g., Faecalibacterium prausnitzii, Roseburia spp.) and lower fecal/plasma SCFA levels, correlating with motor severity, progression, and non-motor symptoms like constipation and depression.
SCFAs counteract these via HDAC inhibition, GPCR activation (e.g., FFAR2/3, GPR109A), and barrier restoration, with preclinical models showing neuroprotection and symptom alleviation.
Recent advances in 2024–2025, including prodrug conjugates and microbiome modulation, position SCFAs as adjuncts to levodopa, addressing dysbiosis-driven treatment resistance.
Key Mechanisms
SCFAs influence PD through interconnected pathways, primarily via microbial metabolite signaling:
- Epigenetic and Neuroprotective Effects:
Butyrate inhibits HDACs, upregulating BDNF/GDNF and promoting autophagy (e.g., via PGC-1α), which degrades α-syn aggregates and protects dopaminergic neurons in MPTP/rotenone models.
Propionate activates FFAR3 to boost GLP-1 secretion, enhancing motor function and reducing neurodegeneration. - Anti-Inflammatory and Immune Modulation:
SCFAs shift microglia from M1 (proinflammatory) to M2 phenotypes via GPR109A/NF-κB inhibition, suppressing cytokines (IL-6, TNF-α) and ROS/RNS-induced oxidative stress.
They promote Treg differentiation and curb gut-to-brain α-syn propagation by stabilizing intestinal barriers (upregulating ZO-1/claudins). - Gut Microbiome and Barrier Integrity:
SCFAs restore eubiosis, inhibit L-dopa-metabolizing bacteria (e.g., Enterococcus faecalis), and enhance vagal signaling for parasympathetic tone, alleviating constipation and systemic inflammation. - α-Synuclein Modulation:
Butyrate reduces phosphorylated α-syn in the substantia nigra via C/EBPβ suppression and autophagy, limiting transneuronal spread from ENS to the brain.
These mechanisms are bidirectional:
PD dysbiosis depletes SCFAs, exacerbating pathology, while SCFA supplementation reverses deficits in germ-free/transplant models.
Evidence from Preclinical and Clinical Studies:
Recent studies highlight SCFAs’ efficacy, with a shift toward targeted delivery and microbiome integration.
Below is a summary of key 2024–2025 findings:
|
Study Type/Source
|
Key Findings
|
Model/Population
|
Outcomes/Implications
|
|---|---|---|---|
|
Preclinical: Honokiol-SCFA Conjugates (Scientific Reports, Jun 2025)
|
Ester prodrugs (e.g., HNK-BAc) hydrolyzed by gut esterases release HNK/SCFAs, inhibiting E. faecalis growth (dose-dependent delay, MIC 180 µM for HNK-Ac) and L-dopa-to-dopamine conversion, preserving bioavailability. Induce membrane hyperpolarization and transient ATP modulation without cytotoxicity.
|
In vitro (E. faecalis cultures); no in vivo yet
|
Enhances levodopa efficacy; synergistic neuroprotection via AMPK-Sirt3 (HNK) and HDAC inhibition (SCFAs). Proposes gut-targeted adjunct therapy; future MitoPark mouse trials needed.
|
|
Review: SCFAs-PD Pathogenesis (Front Neurol, 2024; updated insights 2025)
|
Reduced SCFAs correlate with α-syn aggregation, BBB leakage, and Th17/Treg imbalance. Butyrate rescues TH expression/dopamine in 6-OHDA/MPTP models; propionate protects via FFAR3/GLP-1. Dual effects: anti-inflammatory at low doses, potential exacerbation at high in sterile conditions.
|
MPTP mice, rotenone Drosophila, germ-free models
|
Supports SCFA augmentation for early PD; links to non-motor symptoms (e.g., sleep via circadian entrainment).
|
|
Mechanistic: α-Syn/Neuroinflammation (Redox Biol, 2024)
|
SCFAs modulate α-syn-induced microglial ROS/RNS and inflammation; lower SCFA levels in PD guts promote aggregation as early biomarker. Probiotics restore SCFAs, alleviating symptoms.
|
PD patient microbiomes; in vitro microglia
|
Highlights gut-brain axis; probiotics as SCFA boosters for anti-aggregation therapy.
|
|
Clinical Pilot: Tributyrin (SCFA Prodrug) (NCT05446168, ongoing 2022–2025)
|
Open-label trial assesses oral tributyrin (SCFA precursor) for target engagement in PD, measuring plasma SCFAs, inflammation, and motor scores. Positive preclinical: restores microbiota balance.
|
20 PD patients (Phase 1)
|
Aims to support larger SCFA supplementation studies; potential for symptom relief via gut modulation.
|
|
Clinical Pilot: Prebiotic SR001 (NCT07127120, Aug 2025 initiation)
|
Single-arm trial of prebiotic targeting SCFA-producers (e.g., butyrate via fibers) to evaluate microbiome shifts, fecal SCFAs, and PD progression markers.
|
30 early PD patients
|
Focuses on beneficial metabolites as fuel; early data may inform dietary interventions for dysbiosis.
|
|
FMT/SCFA Regulation (Front Microbiol, Jun 2025)
|
FMT upregulates FFAR2/3, elevating SCFAs and reducing neuroinflammation in PD models; correlates with motor improvements.
|
α-Syn-overexpressing mice
|
Validates microbiota transfer for SCFA restoration; therapeutic for prodromal PD.
|
Therapeutic Applications
SCFAs offer non-invasive, microbiome-centric strategies, often combined with standard care:
- Direct/Indirect Supplementation:
– Oral butyrate (500–2000 mg/day) or prodrugs like tributyrin improve motor scores in models;
– Prebiotics (e.g., inulin, resistant starch) boost endogenous production by 20–50%, enhancing barriers and GLP-1. - Probiotics/Synbiotics: Strains like Bifidobacterium breve or L. rhamnosus GG increase SCFAs, reducing α-syn and inflammation in MPTP mice; RCTs show 15–30% UPDRS improvements.
- Novel Conjugates: HNK-SCFA esters target dysbiosis and L-dopa resistance, with hydrophobicity aiding delivery; 2025 pilots explore oral dosing.
- Dietary Interventions: High-fiber Mediterranean diets elevate SCFAs, correlating with slower PD progression (e.g., negative association with H&Y scores).
Doses are well-tolerated (up to 4 g/day butyrate), but variability arises from microbiome baseline.
Challenges include absorption (colonic targeting via enemas) and context-dependent effects (e.g., inflammation in low-diversity guts).
Future trials (e.g., Phase II for conjugates) integrate multi-omics for personalization, potentially delaying progression by 20–40% via early gut intervention.